An opinion on the commercial prospects of RHY, page-3

I wouldn't say rudimentary, more limited. The main reason I have posted is to make sure I haven't missed something important so thank for your response.

There are other (or at least were) comptitors in the protein-based blood screening. From the prospectus both Applied Proteomics and VolitionRx are listed as offering protein-based blood screening tests. More worrying Applied Proteomics' test seems to have been a commercial failure [1]. They spent US$50 million and sold off their IP for US$1.85 million in 2018. I haven't been through the entire scientific literature, but I have found quite a few research papers on this approach too.

DNA tests don't have to be more expensive than protein based tests, it all really depends on the test design and the lab. Having said this trying to sell a test on cost in this market is really hard. Even if your competitors are more expensive they have a habit of dropping their prices if they know they have deeper pockets - the diagnostic market is a cut-throat industry with some very big players who don't mind playing dirty.

We can agree to disagree on the need for a CR in 2019, but when you are spending $2 million a quarter and have $5 million in the bank and are about to go into a clinical testing program (Study 7) I don't think you have much chance of reaching the end of 2019 without raising more cash.

1. https://www.genomeweb.com/proteomics-protein-research/applied-proteomics-sells-assets-discerndx-185m